Dong-A ST Amends NeuroBo Pharmaceuticals Stake

TL;DR

Dong-A ST updated its NeuroBo stake filing - ownership details changed.

AI Summary

Dong-A ST Co., Ltd. filed an amendment (Amendment #7) to its Schedule 13D on September 20, 2024, regarding its holdings in NeuroBo Pharmaceuticals, Inc. The filing indicates a change in the reporting person's beneficial ownership of NeuroBo's common stock. Specific details on the exact percentage change or new holdings are not immediately available in this excerpt but are the subject of the amendment.

Why It Matters

This filing signals a potential shift in the ownership structure or strategy of NeuroBo Pharmaceuticals, which could impact its stock price and future business decisions.

Risk Assessment

Risk Level: medium — Changes in major shareholder filings can indicate shifts in control or strategy, potentially affecting the company's stock.

Key Players & Entities

• Dong-A ST Co., Ltd. (company) — Reporting Person
• NeuroBo Pharmaceuticals, Inc. (company) — Issuer
• Min Young Kim (person) — Contact Person at Dong-A ST
• Matthew Berger (person) — Legal Counsel
• Michael Brandt (person) — Legal Counsel

FAQ

Key Financial Figures

• $0.001 — ame of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securitie
• $3.75 — of Common Stock at a price per share of $3.75 on September 12, 2024, as reflected in

Filing Documents

• d79047707.htm (SC 13D/A) — 33KB
• 0000899140-24-001035.txt ( ) — 35KB

Purpose

Item 4. Purpose of the Transaction

of this Schedule 13D is hereby amended and supplemented to include the following

Item 4 of this Schedule 13D is hereby amended and supplemented to include the following: Stockholder Approval On September 18, 2024, pursuant to the Securities Purchase Agreements, the Issuer's stockholders approved the issuance of shares of Common Stock upon the exercise of (i) the Series A Warrants; (ii) the Series B Warrants; and (iii) the Placement Agent Warrants, as contemplated by Nasdaq Listing Rule 5635(d).

. Interest

Item 5 . Interest in Securities of the Issuer

(a)-(c) of this Schedule 13D is hereby amended and restated as follows

Item 5(a)-(c) of this Schedule 13D is hereby amended and restated as follows: (a)-(b) The information contained in the cover page and in Item 4 to this Schedule 13D is hereby incorporated by reference into this Item 5. (c) Except as set forth in this Schedule 13D, including the footnotes contained in the cover page incorporated herein, the Reporting Person did not acquire or sell any shares of Common Stock or other securities of the Issuer during the last 60 days. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Date: September 20, 2024 DONG-A ST CO., LTD. By: /s/ Jae Hun Jung Name: Jae Hun Jung Title: Chief Executive Officer

View Full Filing

View this SC 13D/A filing on SEC EDGAR